Outcome

This study found that a 20-day course of hyperbaric oxygen therapy significantly improved cognitive function and brain glucose metabolism in patients with Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). AD patients showed marked improvement in cognitive scores at a 1-month follow-up while aMCI patients exhibited long-term benefits lasting up to 6 months.

Introduction

This study investigates the potential of hyperbaric oxygen therapy (HBOT) as a promising alternative treatment for Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). Understanding that hypoxia or reduced oxygen supply plays a significant role in the development of AD researchers explored how improving oxygen levels in the brain could affect cognitive function. Conducted with 53 patients including 42 with AD and 11 with aMCI the study administered 20 daily HBOT sessions each involving periods of breathing pure oxygen and air under pressure at 1.2 ATA. Results were strikingly positive showing significant improvements in cognitive assessments like the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores especially at follow-ups of one and three months. Functional gains in daily living activities (ADL) were also observed particularly in AD patients. Additionally fluordeoxyglucose positron emission tomography (FDG-PET) scans revealed enhanced brain glucose metabolism underscoring the treatment’s neurological benefits. This evidence suggests that HBOT could be a safe effective way to address cognitive impairments in neurodegenerative conditions warranting further research for broader applications.

Results

The study found that hyperbaric oxygen treatment (HBOT) significantly improved cognitive function in patients with Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). Patients with AD and aMCI who underwent 20 sessions of HBOT showed substantial improvement in their cognitive scores as measured by the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). These improvements were noted at the 1-month follow-up for both patient groups. Additionally Activities of Daily Living (ADL) scores also saw significant improvements in AD patients at both the 1-month and 3-month follow-ups.

In-depth results indicated that treated AD patients had higher MMSE and MoCA scores compared to those in the untreated control group particularly at the 1-month mark. Moreover fluorodeoxyglucose positron emission tomography (FDG-PET) scans revealed that HBOT ameliorated reduced glucose metabolism in various brain regions in both AD and aMCI patients.

Overall the findings suggest that HBOT at 1.2 ATA can enhance cognitive function and brain metabolism providing a potential alternative therapy for cognitive impairment in AD and aMCI patients. The treatment was safe and well-tolerated with improvements in cognitive function lasting up to six months for aMCI patients. These promising results advocate for further research with larger samples multiple treatment sessions and extended follow-up periods to solidify HBOT as a viable therapy option for dementia-related conditions.

Conclusion

In conclusion this study provides strong evidence that hyperbaric oxygen therapy (HBOT) can significantly improve cognitive impairment in patients with Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). A single course of 20 HBOT sessions at 1.2 ATA demonstrated notable improvements in cognitive function as measured by MMSE and MoCA scores with differing durations of benefit across patient groups. Specifically AD patients showed cognitive improvements at a 1-month follow-up while aMCI patients experienced benefits lasting up to 6 months.

Moreover activities of daily living (ADL) scores also improved for AD patients indicating enhanced overall functionality. FDG-PET scans revealed that HBOT ameliorated reduced glucose metabolism in various brain regions further supporting the therapy’s positive impact on brain health.

While these results are promising pointing to HBOT as a potential alternative therapy for AD and aMCI the study underscores the need for further research. Future studies should investigate larger sample sizes multiple treatment courses and longer follow-up periods to determine the full potential and longevity of HBOT’s benefits.

This study contributes valuable insights into managing cognitive impairments associated with AD and aMCI highlighting the potential of HBOT to improve quality of life in these populations.